Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Home
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Next Post
Previous Post
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
October 12, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Read More
Emma Reeve
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with
nab
-sirolimus, showing durability of response and long-term safety
Weekly
nab
-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Read More
Dave Lennon
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.